US 11026905
STAT3 inhibitors
granted A61KA61K31/18
Quick answer
US patent 11026905 (STAT3 inhibitors) held by Tvardi Therapeutics, Inc. expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Tvardi Therapeutics, Inc.
- Grant date
- Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/18